Please assess the completion status of the following clinical trial:

Trial Title: Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Proliferative Diabetic Retinopathy~* Best Corrected Visual Acuity (BCVA) in study eye of at least 20 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (20/400)~* Type 1 or type 2 diabetes under medical surveillance / with stabilized treatment~Exclusion Criteria:~* Proliferative vitreoretinopathy in study eye~* Clinically significant macular edema (CSME) in the study eye~* Clinically non significant macular edema (CNSME) that is likely to develop to CSME in the study eye~* Uncontrolled glaucoma in either eye~* Other protocol-specified conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab mono (Type: EXPERIMENTAL): Interventional Core Phase: One intravitreal injection of ranibizumab 0.5 mg to the study eye monthly until stability regarding morphological parameters is confirmed (ie, no further improvement of morphology or no worsening of morphology for 3 consecutive months)
- PRP mono (Type: ACTIVE_COMPARATOR): Interventional Core Phase: Panretinal laser photocoagulation (PRP) treatment administered to the study eye in accordance with the modified diabetic retinopathy study (DRS) guidelines for panretinal laser photocoagulation procedures
- Ranibizumab+PRP (Type: EXPERIMENTAL): Interventional Core Phase: Ranibizumab 0.5 mg as described for the ranibizumab mono arm and PRP treatment as described for the PRP mono arm until stability regarding morphological parameters is confirmed

Based on this trial design, predict the completion outcome and termination type (if applicable).